<DOC>
	<DOCNO>NCT00202605</DOCNO>
	<brief_summary>The purpose study evaluate safe well SPD465 work compare placebo adult ADHD . It hypothesize SPD465 achieve extend duration clinical benefit .</brief_summary>
	<brief_title>Safety Efficacy SPD465 Adults With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>Primary diagnosis ADHD use DSMIVTR criterion ( least 6 9 subtype criterion meet ) Baseline ADHDRSIV score = &gt; 24 IQ score = &gt; 80 ( use Kaufman Brief Intelligence Test ) BMI &lt; 18.5 &gt; 30 kg/m2 Diagnosis Post Traumatic Stress Disorder , psychosis , bipolar illness , severe obsessive compulsive disorder , severe depressive severe anxiety disorder History seizure disorder lifetime history seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or family history Tourette 's Disorder History uncontrolled hypertension currently hypertensive Subjects take atomoxetine ( STRATTERA ) within 30 day prior screen Current ( history within last 12 month ) drug dependence substance abuse disorder accord DSMIVTR criterion ( exclude nicotine ) Female subject pregnant lactating , less 3 month post partum</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>